ECOG-ACRIN Cancer Research Group shared a post on X:
“Monika Joshi and Petros Grivas are leading Clinical Trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced Urothelial Cancer.”
Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared this post, adding:
“Merry Christmas and Happy Holidays!
Please consider opening this important phase 3 trial asking the major ICI rechallenge question in advanced urothelial cancer! ”
More posts featuring Petros Grivas.